These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 38923896

  • 1. Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B.
    Pauly N, Burrell A, Drelich D, Zhang X, Thiruvillakkat K, Nysenbaum J, Fiori A, Yan S.
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1095-1105. PubMed ID: 38923896
    [Abstract] [Full Text] [Related]

  • 2. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
    Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S.
    J Manag Care Spec Pharm; 2024 Aug; 30(8):805-816. PubMed ID: 38625717
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY, Johnson A, Cooke CE, Yared JA, Summers A, Yang K, Liu S, Tang B, Onukwugha E.
    J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model.
    Li N, Sawyer EK, Maruszczyk K, Guzauskas G, Slomka MT, Burke T, Martin AP, O'Hara J, Stevenson M, Recht M.
    J Med Econ; 2021 May; 24(1):363-372. PubMed ID: 33591884
    [Abstract] [Full Text] [Related]

  • 11. Bleeds and resource use in hemophilia B: retrospective observational study.
    Young L, Ban L, Chen Y, Fogarty PF.
    Am J Manag Care; 2024 May 01; 30(5):e157-e164. PubMed ID: 38748916
    [Abstract] [Full Text] [Related]

  • 12. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.
    J Manag Care Spec Pharm; 2018 Jul 01; 24(7):643-653. PubMed ID: 29363389
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
    Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, Markan R, Farahbakhshian S.
    J Manag Care Spec Pharm; 2023 Jun 01; 29(6):626-634. PubMed ID: 37276033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
    Ay C, Perschy L, Rejtö J, Kaider A, Pabinger I.
    Ann Hematol; 2020 Dec 01; 99(12):2763-2771. PubMed ID: 32918114
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.